Literature DB >> 19585288

The cost of relapse in schizophrenia and schizoaffective disorder.

Paul Fitzgerald1, Anthony de Castella, Dinesh Arya, W Robert Simons, Andrew Eggleston, Sharon Meere, Jayashari Kulkarni.   

Abstract

OBJECTIVE: The aim of this study was to quantify the costs and resource utilization associated with a relapse of schizophrenia or schizoaffective disorder.
METHODS: The study comprised a retrospective audit of data from 200 patients diagnosed with schizophrenia or schizoaffective disorder who were admitted to hospital for a relapse of their disorder in two mental health services in Australia between 1 June 2001 and 31 May 2002. Resource use and costing data were collected for 12 months before and 12 months after the hospitalization.
RESULTS: There was an increase in contacts per month and associated outpatient costs after the index admission which persisted for the full 12 month data collection period (total of AUD $637). There was also a total increase in hospital costs but this did not persist beyond the first 2 months of the follow-up period and is likely explained by the index admission.
CONCLUSIONS: Increased healthcare resource utilization and costs results from relapse in patients with schizophrenia or schizoaffective disorder. An increase in service use and costs persist for a considerable time period after an episode of relapse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19585288     DOI: 10.1080/10398560903002998

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  5 in total

Review 1.  The Cost of Relapse in Schizophrenia.

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

2.  New Zealand community mental healthcare provider experience in schizophrenia management with 3-monthly paliperidone palmitate.

Authors:  Cathal Cassidy; Wayne Miles
Journal:  Australas Psychiatry       Date:  2020-06-25       Impact factor: 1.369

3.  Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study.

Authors:  Rafal A H Yeisen; Jone Bjornestad; Inge Joa; Jan Olav Johannessen; Stein Opjordsmoen
Journal:  BMC Psychiatry       Date:  2017-08-22       Impact factor: 3.630

4.  Claims-based proxies of patient instability among commercially insured adults with schizophrenia.

Authors:  Charles Ruetsch; Hyong Un; Heidi C Waters
Journal:  Clinicoecon Outcomes Res       Date:  2018-05-07

5.  Understanding Implementation of a Digital Self-Monitoring Intervention for Relapse Prevention in Psychosis: Protocol for a Mixed Method Process Evaluation.

Authors:  Stephanie Allan; Hamish Mcleod; Simon Bradstreet; Sara Beedie; Bethany Moir; John Gleeson; John Farhall; Emma Morton; Andrew Gumley
Journal:  JMIR Res Protoc       Date:  2019-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.